RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB

被引：0
|
作者：
Giacomini, E. [1 ]
Leogrande, M. [2 ]
Motta, L. [3 ]
Tempre, R. [4 ]
Bendinelli, S. [4 ]
Degli Esposti, L. [2 ]
机构：
[1] CliCon Srl, Societa Benefit Hlth Econ & Outcomes Res, Bologna, Italy
[2] CliCon Srl, Societa Benefit Hlth Econ & Outcomes Res, Bologna, BO, Italy
[3] Roche SpA, Monza, Italy
[4] Roche SpA, Monza, MB, Italy
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE96
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] Emicizumab Prophylaxis in Patients with Hemophilia. with and without Inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    BLOOD, 2019, 134
  • [2] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
  • [3] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [4] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [5] AN ITALIAN PHARMACOUTILIZATION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS AFTER SWITCHING TO EMICIZUMAB
    Perrone, V
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Ferrario, M.
    Esposti, L. Degli
    VALUE IN HEALTH, 2024, 27 (12)
  • [6] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [7] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [8] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
  • [9] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Aledort, Louis M.
    Ewenstein, Bruce M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2193 - 2193
  • [10] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Oldenburg, Johannes
    Mahlangu, Johnny N.
    Kim, Benjamin
    Schmitt, Christophe
    Callaghan, Michael U.
    Young, Guy
    Santagostino, Elena
    Kruse-Jarres, Rebecca
    Negrier, Claude
    Kessler, Craig
    Valente, Nancy
    Asikanius, Elina
    Levy, Gallia G.
    Windyga, Jerzy
    Shima, Midori
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 809 - 818
12345